NO20052277L - Behandling av syndrom X med substituerte tetraliner og indaner - Google Patents

Behandling av syndrom X med substituerte tetraliner og indaner

Info

Publication number
NO20052277L
NO20052277L NO20052277A NO20052277A NO20052277L NO 20052277 L NO20052277 L NO 20052277L NO 20052277 A NO20052277 A NO 20052277A NO 20052277 A NO20052277 A NO 20052277A NO 20052277 L NO20052277 L NO 20052277L
Authority
NO
Norway
Prior art keywords
indanes
syndrome
treatment
substituted tetralines
tetralines
Prior art date
Application number
NO20052277A
Other languages
English (en)
Other versions
NO20052277D0 (no
Inventor
Keith Demarest
Jay M Matthews
Xiaoli Chen
Jung Lee
Philip Rybczynski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20052277D0 publication Critical patent/NO20052277D0/no
Publication of NO20052277L publication Critical patent/NO20052277L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/08—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår tetralin- og indanforbindelser med formel (I), sammensetninger som inneholder dem, og fremgangsmåte for anvendelse av dem som PPAR alfa modulatorer for å behandle eller inhibere progresjon av for eksempel diabetes.
NO20052277A 2002-10-21 2005-05-10 Behandling av syndrom X med substituerte tetraliner og indaner NO20052277L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41992702P 2002-10-21 2002-10-21
US49575803P 2003-08-15 2003-08-15
PCT/US2003/033088 WO2004037777A1 (en) 2002-10-21 2003-10-17 Treating syndrome x with substituted tetralins and indanes

Publications (2)

Publication Number Publication Date
NO20052277D0 NO20052277D0 (no) 2005-05-10
NO20052277L true NO20052277L (no) 2005-06-29

Family

ID=32179770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052277A NO20052277L (no) 2002-10-21 2005-05-10 Behandling av syndrom X med substituerte tetraliner og indaner

Country Status (17)

Country Link
US (2) US20040171680A1 (no)
EP (1) EP1556344A1 (no)
JP (1) JP2006503915A (no)
KR (1) KR20050067419A (no)
AU (1) AU2003279981A1 (no)
BR (1) BR0315566A (no)
CA (1) CA2503405A1 (no)
CO (1) CO5690541A2 (no)
EA (1) EA200500517A1 (no)
HR (1) HRP20050337A2 (no)
MX (1) MXPA05004296A (no)
NO (1) NO20052277L (no)
NZ (1) NZ539432A (no)
PL (1) PL376470A1 (no)
RS (1) RS20050319A (no)
TW (1) TW200412935A (no)
WO (1) WO2004037777A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100989394B1 (ko) * 2002-10-21 2010-10-25 얀센 파마슈티카 엔.브이. 치환된 테트라린 및 인단 및 그 용도
NZ539510A (en) * 2002-10-21 2008-01-31 Janssen Pharmaceutica Nv Substituted tetralin and indane derivatives
KR20060060047A (ko) 2003-10-01 2006-06-02 더 프록터 앤드 갬블 캄파니 멜라닌 농축 호르몬 길항제
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
CA2583454A1 (en) * 2004-10-12 2006-04-27 Pharmacopeia Drug Discovery, Inc. Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
US20060263450A1 (en) * 2005-05-17 2006-11-23 Julius Oben Method and composition for reducing body weight and improving control of body lipids
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
US20100098792A1 (en) * 2008-10-17 2010-04-22 Gateway Health Alliances, Inc. Methods and compositions using irvingia gabonensis to reduce weight, control obesity, effect adipogenesis, lower ppar-gamma, leptin, g3pdh and triglycerides levels and increase adiponectin levels
US20100098793A1 (en) * 2008-10-17 2010-04-22 Gateway Health Alliances, Inc. Irvingia gabonensis to treat and prevent metabolic syndrome and reduce total cholesterol, ldl cholesterol, blood glucose, c-reactive protein, and leptin levels and increasing adiponectin levels
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy
WO2016092546A1 (en) * 2014-12-09 2016-06-16 Ezekiel Golan Binge behavior regulators
WO2016092547A1 (en) 2014-12-09 2016-06-16 Ezekiel Golan Alcoholic beverage substitutes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
CA2400021A1 (en) * 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
SK4132003A3 (en) * 2000-10-05 2004-02-03 Bayer Ag Propionic acid derivatives, the process for their preparation, pharmaceutical composition comprising them, use thereof and intermediates for producing them
WO2002044129A1 (fr) * 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Dérivés d'acide carboxylique substitués
AU2002222573A1 (en) * 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
AU2002233271A1 (en) * 2000-12-20 2002-07-01 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists
US6548538B2 (en) * 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
KR100989394B1 (ko) * 2002-10-21 2010-10-25 얀센 파마슈티카 엔.브이. 치환된 테트라린 및 인단 및 그 용도
NZ539510A (en) * 2002-10-21 2008-01-31 Janssen Pharmaceutica Nv Substituted tetralin and indane derivatives

Also Published As

Publication number Publication date
MXPA05004296A (es) 2005-11-23
WO2004037777A1 (en) 2004-05-06
JP2006503915A (ja) 2006-02-02
RS20050319A (en) 2007-09-21
PL376470A1 (en) 2005-12-27
US20040162352A1 (en) 2004-08-19
EP1556344A1 (en) 2005-07-27
AU2003279981A1 (en) 2004-05-13
CO5690541A2 (es) 2006-10-31
US20040171680A1 (en) 2004-09-02
NZ539432A (en) 2008-04-30
BR0315566A (pt) 2005-08-23
HRP20050337A2 (en) 2005-12-31
CA2503405A1 (en) 2004-05-06
TW200412935A (en) 2004-08-01
KR20050067419A (ko) 2005-07-01
EA200500517A1 (ru) 2005-10-27
NO20052277D0 (no) 2005-05-10

Similar Documents

Publication Publication Date Title
NO20052277L (no) Behandling av syndrom X med substituerte tetraliner og indaner
NO20062511L (no) Fenoksy-eddiksyrederivater anvendelige som peroksisomproliferator-aktiverende reseptor (PPAR) dualagonister
DK1599468T3 (da) 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20081196L (no) Terapeutisk middel for diabetes
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20044351L (no) Heterocyklo inhibitorer av kalsiumkanal funksjonen
NO20076515L (no) Hydantoinforbindelser
NO20071222L (no) Benzamidforbindelser.
BRPI0610644B8 (pt) composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
NO20071919L (no) 4-((fenoksyalkyl)tio)-fenoksyeddiksyre og analoger
CY1110326T1 (el) Υποκατασταθεισες τετραλινες και ινδανια και η χρηση τους
NO20061711L (no) 4-((fenoksylalkyl)tio)fenoksyeddiksyre og analoger
NO20063342L (no) Nye forbindelser
NO20071920L (no) 4-((fenoksyalkyl)tio)-fenoksyeddiksyre og analoger
NO20052199L (no) Substituerte tetraliner og indaner
ATE372330T1 (de) N-sulfonylurea-apoptosis-förderer
ATE539756T1 (de) Prostaglandinsubstanzen für die behandlung von fettsucht
DK1656360T3 (da) Thiazolinderivater som selektive androgenreceptor-modulatorer
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
NO20062700L (no) Morfolinderivater som norepinefrin reopptaksinhibitorer
NO20071107L (no) 1,1,2,2-tetra(hetero)aryletaner eller 1,1,2-tri(hetero)aryl-2-heterosyklyletaner som kaliumkanalinhibitorer
NO20061427L (no) Kombinasjonen av en serotonin-reoppttaksinhibitor og amoxapin
SE0301794D0 (sv) New use III
RS20060322A (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides